

## DAFTAR PUSTAKA

- Abraham, W.T., Krum, H., 2007. *Heart Failure A Practical Approach to Treatment*. USA : The McGraw-Hill Companies, Inc. pp 83-88
- ACCF/AHA. 2013. ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation*. 128:e240-e327.
- AHA, 2013. *About Cardiac Arrest*, diakses dari [http://www.heart.org/HEARTORG/Conditions/More/CardiacArrest/About-Cardiac-Arrest\\_UCM\\_307905\\_Article.jsp](http://www.heart.org/HEARTORG/Conditions/More/CardiacArrest/About-Cardiac-Arrest_UCM_307905_Article.jsp) pada tanggal 23 Juli 2014.
- American Society of Health-System Pharmacists. 2011. *AHFS Drug Information Essential*. Maryland : American Society of Health-System Pharmacists, inc.
- Barrett, K.E., Barman, S.M., Boitano, S., Brooks, H., 2010. *Ganong's Review of Medical Physiology*. 23<sup>rd</sup> Edition. USA : McGraw-Hill Medical. pp 508.
- Bauters, C., Lamblin, N., Fadden, E.P.Mc., Belle, E.V., Millaire, A., Groote, P.De., Influence of diabetes mellitus on heart failure risk and outcome. *Cardiovasc Diabetol*. 2(1)
- Baxter, S., 2010. *Stockley's Drug Interaction : ACE – inhibitors*. London : Pharmaceutical Press. Pp : 12-15
- Benzie, I.F.F., Tomlinson, B., 1998. Antioxidant power of angiotensin-converting enzyme inhibitors *in vitro*. *Br J Clin Pharmacol*. 45(2): 168–169.
- Braunwald, E., 2005. Heart Failure and Cor Pulmonale. In : Kasper, D.L., Braunwald E., Fauci, A.S., Hauser, S.L., Longo, D.L., Jameson, J.L., (eds). *Harrison's Principle of Internal Medicine*. 16<sup>th</sup> Edition. New York: McGraw Hill. pp 607-640

Brunton, L., Lazo J., Parker K., 2006. ***Goodman and Gilman's The Pharmacological Basis of Therapeutics***. United State of America : McGraw-Hill Companies, Inc. pp 737-898.

Carretero, O.A., Xu, J., Shesely, E.G., Rhaleb, N., Yang, J.J., Bader, M., Yang, X., 2009. The kinin B1 receptor contributes to the cardioprotective effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in mice . ***Exp Physiol***. 94(3): 322–329.

Cooper, W.O., Hernandez-Diaz, S., Arbogast, P.A., Dudley, J.A., Dyer, S., Gideon, P.S., Hall, K., and Ray, W.A., 2006. Major Congenital Malformations after First-Trimester Exposure to ACE Inhibitors. ***N Engl J Med***. 354:2443-51.

Davey, Patrick. 2005. ***At a Glance Medicine***. Jakarta : Erlangga. pp 77-79

Departemen Kesehatan Republik Indonesia. 2009. ***Profil Kesehatan Indonesia 2008***. Jakarta.

Dicpinigaitis, Peter V., 2006. Angiotensin-Converting Enzyme Inhibitor-Induced Cough - ACCP Evidence-Based Clinical Practice Guidelines. ***Chest***. 129 : 169s-173s

Dunlay, S.M., Weston, S.A., Jacobsen, S.J., Roger, V.L., 2009. Risk Factors for Heart Failure: A Population – Based Case – Control Study. ***Am J Med***. 122 (11).

Dykewicz, M.S., 2004. Cough and Angioedema From Angiotensin-Converting Enzyme Inhibitors: New Insights Into Mechanisms and Management. ***Curr Opin Allergy Clin Immunol***. 4:4

ESC (European Society of Cardiology). 2004. Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. ***Eur Heart J***. 25: 1454–1470.

ESC (European Society of Cardiology). 2012. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. ***Eur Heart J***. 33: 1787–1847.

Facts and Comparisons. 2009. ***Drug Facts & Comparisons: Pocket Version***, 2009 Edition.

Garg, R., Yusuf, S., Bussman, W.D., Sleight, P., Uprichard, A., Massie, B., McGrath, B., Nilsson, B., Pitt, B., Magnani, B., Maskin, C., Ambrosioni, E., Rucinska, E., Kleber, F.X., Jennings, G., Tognoni, G., Drexler, H., Cleland, J.G.F., Franciosa J.A., Remes, J., Swedberg, K., Dickstein, K., Maass, L., Pfeffer, M., Creager, M.A., Gordon, M., Joy, M., Shape, N., Desche, P., McGarry, R., Collins, R., Chrysant, S.G., Cicchetti, V., 1995. Overview of Randomized Trials of Angiotensin-Converting Enzyme Inhibitors on Mortality and Morbidity in Patient With Heart Failure. *JAMA*. 273 (18):1450-1456

Gianni, M., Bosch J., Pogue, J., Probstfield, J., Dagenais, G., Yusuf, S., Lonn, E., 2007. Effect of long-term ACE-inhibitor therapy in elderly vascular disease patients. *Eur Heart J* : 28, 1382–1388.

Gibbs, C.R., Jackson, G., Lip, G.Y.H., 2000. ABC of Heart Failure : Non-Drug Management. *BMJ*. 320:366-9.

Gottlieb, Scott. 2004. Study warns of danger of combining spironolactone and ACE inhibitors in heart patients. *BMJ*. 329(7463): 420.

He, J., Ogden, L.G., Bazzano, L.A., Vupputuri, S., Loria, C., Whelton, P.K., 2001. Risk Factors for Congestive Heart Failure in US Men and Women. *Arch Intern Med*. 161 : 996 – 1002.

Hemels ME, Bennet HA, Bonari L. 2003: HOPE Study Impact on ACE Inhibitors Use. *Ann Pharmacother*.37: 640–45.

Holecki M, Szewieczek J, Chudek J. 2011 : Effect of angiotensin-converting enzyme inhibitors beyond lowering blood pressure – are they important for doctors? *Pharmacological Report*.63: 740–51

Jackson, E.K., 2006. Renin and Angiotensin. In :*Goodman and Gilman's The Pharmacological Basis of Therapeutics*, 11<sup>th</sup> edition. United State of America : McGraw-Hill Companies, Inc. pp 1037-1044

Jafar TH, Stark PC, Schimd CH. 2003 : AIPRD Study Group : Progression of chronic kidney disease : the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition : a patient-level meta-analysis. *Ann Intern Med*.139: 244–52.

- Katzung, B.G., Parmley, W.W., 2010. Drug Used In Heart Failure. In : Bertram G. Katzung (eds). ***Basic and Clinical Pharmacology***. 12th Edition. US : McGraw-Hill Companies. pp 211.
- Keinchaiah, S., Evans, J.C., Levy, D., Wilson, P.W.F., Benjamin, E.J., Larson, M.G., Kannel W.B., Vasani, R.S., 2002. Obesity and The Risk of Heart Failure. ***N Engl J Med***. 347(5)
- Khattar, R.S., Senior, R., Soman, P., van der Does, R., Lahiri, A., 2001. Regression of left ventricular remodeling in chronic heart failure: Comparative and combined effects of captopril and carvedilol. ***Am Heart J***. 142(4):704-13.
- Lakdawala, N.K., Desai A., 2010. Medical Therapy for Heart Failure. In : Maisel, W.H., ***Device Therapy in Heart Failure***. USA : Humana Press. pp: 37-42
- Lee, D., and Bergman, U., 2012. Studies of Drug Utilization. In : Strom, B.L., Kimmel, S.E., Hennessy, S., ***Pharmacoepidemiology***. 5<sup>th</sup> ed. UK : John Wiley & Sons, Ltd. pp. 379-380
- Lip, G.Y.H., Gibbs, C.R., Beevers D.G., 2000. ABC of Heart Failure : Aetiology. ***BMJ***. 320:366-9.
- Mann, D.L. 2008. Heart Failure and Cor Pulmonale. In : Kasper, D.L., Braunwald E., Fauci, A.S., Hauser, S.L., Longo, D.L., Jameson, J.L., Loscalzo, J (eds). ***Harrison's Principle of Internal Medicine***. 17<sup>th</sup> Edition. New York: McGraw Hill. pp 1443.
- Marieb, E.N., Hoehn, K., 2007. ***Human Anatomy and Physiology***. 7<sup>th</sup> ed. San Francisco : Benjamin Cummings Science. pp: 678-700
- Marsha A. Raebel. 2012 Hyperkalemia Associated with Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers. ***Cardiovascular Therapeutics***. 30: e156–e166
- Martini, F.H., Nath, J.L., Bartholomew, E.F., 2012. ***Fundamentals of anatomy & physiology***. 9<sup>th</sup> ed. USA : Pearson Education, Inc. pp: 670-702

Mateti, U.V., Nekkanti, H., Vilakkathala, R., Rajakannan, T., Mallayasamy, S., Ramachandran, P., 2012. Pattern of Angiotensin-Converting Enzyme Inhibitors Induced Adverse Drug Reactions in South Indian Teaching Hospital. *N Am J Med Sci.* 4(4): 185–189.

McMurray, J., Cohen-Solal, A., Dietz, R., Eichhorn, E., Erhardt, L., Hobbs, F.D.R., Krum, H., Maggioni, A., McKelvie, R.S., Pin˜a, I.L., Soler-Soler, J., Swedberg, K., 2005. Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: Putting guidelines into practice. *EJHF.* 7 : 710 – 721.

McMurray, J.J., Stewart, Simon. 2000. Epidemiology, aetiology, and prognosis of heart failure. *Heart.* 83: 596–602

Mukae, S., Aoki, S., Itoh, S., Iwata, T., Ueda, H., Katagiri, T., 2000. Bradykinin B2 Receptor Gene Polymorphism Is Associated With Angiotensin – Converting Enzyme Inhibitor – Related Cough. *Hypertension.* 36 : 127-131

National Heart, Lung, and Blood Institute. 2006. *Incidence and Prevalence: 2006 Chart Book on Cardiovascular and Lung Diseases.*

Neal, M.J., 2012. *Medical Pharmacology At a Glance.* 7<sup>th</sup> ed. UK : John Wiley & Sons, Ltd. pp 42-43

Opie, Lionel H. 2013. *Drugs For the Heart.* 8th ed. Philadelphia : Elsevier Inc. pp 119-133.

Packer, M., Poole-Wilson, P.A., Armstrong, P.W., Cleland, J.G.F., Horowitz, J.D., Massie, B.M., Ryden, L., Thygesen, K., Uretsky, B.F., 1999. Comparative Effect of Low and High Doses of the Angiotensin-Convertig Enzyme Inhibitor, Lisinopril, on Morbidity and Mortality in Chronic Heart Failure. *Circulation.* 100: 2312-2318.

Palmer, B.F., 2004. Managing Hyperkalemia Caused by Inhibitors of the Renin–Angiotensin–Aldosterone System. *N Engl J Med.* 351:585-92.

Parker, R.B., Cavallari, L.H., 2011. Systolic Heart Failure. In : Dipiro, J.T., Talbert, R.L., Yee, G.C., Matzke, G.R., Wells, B.G., Posey, L.M., ***Pharmacotherapy a Pathophysiologic Approach***. USA: The McGraw-Hill Companies, Inc.

Pereira, C., 2009. ***Angiotensin Converting Enzyme Inhibitors (ACEIs) - Clinical Pearls for the Washington Rx Therapeutic Interchange Program (TIP)***. Diakses dari <http://www.bitlib.net/view.php?doc=aHR0cDovL2FlaG9sbGFuZC5jb20vdGljYWwlaW5oaWJpdG9yczQwNC5wZGY> pada tanggal 24 Agustus 2014.

Peterson, J.G., Lauer, M.S., 2001. Using aspirin and ACE inhibitors in combination: Why the hullabaloo?. ***CCJM***. 68(6)

Pfeffer, M.A., Braunwald, E., Moye, L.A., 1992. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after f infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. ***N Engl J Med***. 327:669–77.

Pharmaceutical Care Network Europe Foundation. 2010. ***Classification for Drug Related Problems***. Europe.

Price, S. A., Wilson, L.M. 2006. ***Patofisiologi Konsep Klinis Proses – Proses Penyakit***, edisi 6. Jakarta : EGC. pp 631-641

Rogers, Kara. 2011. ***The Cardiovascular System (The Human Body)***. 1<sup>st</sup> ed. New York : Britannica Educational Publishing, Rosen Educational Services. pp: 21-32

Sadjadi, S.A., McMillan, J.I., Jaipaul, N., Blakely, P., Hline, S.S., 2009. A comparative study of the prevalence of hyperkalemia with the use of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers. ***Ther Clin Risk Manag***. 5: 547–552.

Sica, D.A., Black, H.R., 2002. Angioedema in Heart Failure: Occurrence With ACE Inhibitors and Safety of Angiotensin Receptor Blocker Therapy. ***CHF***. 8(6).

Tanaka Y, Nagal M, Date T, Okada T, Abe Y, Seki S. 2004. Effects of Bradykinin on Cardiovascular Remodeling in Renovascular Hypertensive Rats. ***Hypertens Res***. 27(11): 865–75.

The ONTARGET Investigators. 2008: Telmisartan, ramipril, or both in patients at high risk for vascular events. *N Engl J Med*. 358: 1547–59.

Tran, M.T., Tighe, D.A., Donovan, J.L., Cook, J.R., 2010. *Cardiology Drug Guide*. USA : Jones and Bartlett Publishers, LLC. pp 90.

Velez, M., Sweitzer, N.K., 2010. Pathophysiology of Heart Failure. In : Maisel, W.H., *Device Therapy in Heart Failure*. USA : Humana Press. pp: 1-3

Weinhaus, A.J., Roberts, K.P., 2005. Anatomy of the Human Heart. In : Iaizzo, P.A., *Handbook Of Cardiac Anatomy, Physiology, And Devices*. New Jersey : Humana Press Inc. pp. 51-52

Wyskida, K., Jura-Szolty, E., Smertka, M., Owczareka, A., Chudek, J., 2012. Factors that favor the occurrence of cough in patients treated with ramipril – a pharmacoepidemiological study. *Med Sci Monit*. 18(9): P121-28

Yancy, C.W., Young, J.B., 2008. *Therapeutic Strategies in Heart Failure*. USA : Clinical Publishing Oxford. pp 47-53